RTTNews | Dec 15, 2020 10:05AM EST

10:04 Tuesday, December 15, 2020 (RTTNews.com) - Shares of nano-cap company Anchiano Therapeutics Ltd. (ANCN) are currently soaring 130% after the preclinical biopharmaceutical company announced a merger deal with clinical-stage biotech company Chemomab Ltd.

ANCN is currently trading at $3.595, up $2.055 or 133.44%, on the Nasdaq.

Anchiano Therapeutics and Chemomab, a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, entered into a definitive merger agreement pursuant to which the shareholders of Chemomab would become the majority holders of the combined company.

The proposed merger will create a public company focused on advancing Chemomab's lead product, CM-101.

Read the original article on RTTNews ( https://www.rttnews.com/3153885/stock-alert-anchiano-therapeutics-soars-130-on-merger-deal-with-chemomab.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved